An Update on Diagnosis, Treatment, and Prevention of Clostridium difficile-Associated Disease

Gastroenterology Clinics of North America

Volumn 35, Issue 2, 2006, Pages 315-335

  Aslam, Saima ^a,b   Musher, Daniel M ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; BACITRACIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COLESTIPOL; COLESTYRAMINE; DIPHENOXYLATE; FUSIDIC ACID; GATIFLOXACIN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MACROLIDE; METHYLPREDNISOLONE; METRONIDAZOLE; NITAZOXANIDE; OPT 80; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; RIFALAZIL; RIFAMPICIN; RIFAXIMIN; TEICOPLANIN; TIACUMICIN B; TOVELAMER; TOXIN ANTIBODY; TOXOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; DIAGNOSTIC TEST; DIARRHEA; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FECES LEVEL; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; ENVIRONMENTAL FACTOR; EPIDEMIC; HEALTH CARE POLICY; HOSPITAL INFECTION; HUMAN; IMAGING SYSTEM; IMMUNOGENICITY; IMMUNOPATHOGENESIS; INFECTION CONTROL; MORBIDITY; MORTALITY; NONHUMAN; PREVENTIVE MEDICINE; PSEUDOMEMBRANOUS COLITIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; TOXIC MEGACOLON; TRAVELLER DIARRHEA; VACCINATION;

CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS;

EID: 33746333279     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2006.03.009     Document Type: Review

References (180)

1. McFarland L.V. Diarrhea acquired in the hospital. Gastroenterol Clin North Am 22 3 (1993) 563-577
2. Bartlett J.G. Clostridium difficile: clinical considerations. Rev Infect Dis 12 Suppl 2 (1990) S243-S251
3. Bartlett J.G. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 346 5 (2002) 334-339
4. Olson M.M., Shanholtzer C.J., Lee Jr. J.T., et al. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 15 6 (1994) 371-381
5. Kyne L., Warny M., Qamar A., et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357 9251 (2001) 189-193
6. Moshkowitz M., Ben Baruch E., Kline Z., et al. Clinical manifestations and outcome of pseudomembranous colitis in an elderly population in Israel. Isr Med Assoc J 6 4 (2004) 201-204
7. Pepin J., Valiquette L., Alary M.E., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171 5 (2004) 466-472
8. Musher D.M., Aslam S., Logan N., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40 11 (2005) 1586-1590
9. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 23 (2005) 2442-2449
10. Pepin J., Alary M.E., Valiquette L., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40 11 (2005) 1591-1597
11. Kyne L., Hamel M.B., Polavaram R., et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 34 3 (2002) 346-353
12. Wilcox M.H., Cunniffe J.G., Trundle C., et al. Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect 34 1 (1996) 23-30
13. Antibiotics, staphylococcal enteritis and pseudomembranous enterocolitis. N Engl J Med 249 1 (1953) 37-40
14. Lundsgaard-Hansen P., Senn A., Roos B., et al. Staphylococcic enterocolitis. Report of six cases with two fatalities after intravenous administration of N-(pyrrolidinomethvl) tetracycline. JAMA 173 (1960) 1008-1013
15. Keidan S.E., and Sutherland I.F. Staphylococcal pseudomembranous enterocolitis. Lancet 267 6848 (1954) 1125-1126
16. Williams E. Staphylococcal pseudomembranous enterocolitis complicating treatment with aureomycin. Lancet 267 6846 (1954) 999-1000
17. Friedell G.H., and Paige E. Pseudomembranous enterocolitis following antibiotic therapy for pneumonia: report of a case. Am J Clin Pathol 24 10 (1954) 1159-1164
18. Baden W.F. Staphylococcal and subsequent candida albicans enterocolitis complicating novobiocin therapy. Am J Obstet Gynecol 74 1 (1957) 47-52
19. Tedesco F.J., Barton R.W., and Alpers D.H. Clindamycin-associated colitis. A prospective study. Ann Intern Med 81 4 (1974) 429-433
20. Bartlett J.G., Onderdonk A.B., Cisneros R.L., et al. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis 136 5 (1977) 701-705
21. Rifkin G.D., Fekety F.R., and Silva Jr. J. Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin. Lancet 2 8048 (1977) 1103-1106
22. Larson H.E., and Price A.B. Pseudomembranous colitis: presence of clostridial toxin. Lancet 2 8052-3 (1977) 1312-1314
23. Bartlett J.G., Chang T.W., Gurwith M., et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 298 10 (1978) 531-534
24. Bartlett J.G., Moon N., Chang T.W., et al. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 75 5 (1978) 778-782
25. Hall I.C., and O'Toole E. Intestinal flora in new-born infants with a description of a new pathogenic anaerobe: Bacillus difficilis. Am J Dis Child 48 (1935) 390-402
26. Triadafilopoulos G., Pothoulakis C., O'Brien M.J., et al. Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology 93 2 (1987) 273-279
27. Pothoulakis C., Sullivan R., Melnick D.A., et al. Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. J Clin Invest 81 6 (1988) 1741-1745
28. Miller P.D., Pothoulakis C., Baeker T.R., et al. Macrophage-dependent stimulation of T cell-depleted spleen cells by Clostridium difficile toxin A and calcium ionophore. Cell Immunol 126 1 (1990) 155-163
29. McEllistrem M.C., Carman R.J., Gerding D.N., et al. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 40 2 (2005) 265-272
30. Warny M., Pepin J., Fang A., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366 9491 (2005) 1079-1084
31. Viscidi R., Willey S., and Bartlett J.G. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 81 1 (1981) 5-9
32. McFarland L.V., Mulligan M.E., Kwok R.Y., et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320 4 (1989) 204-210
33. Johnson S., Clabots C.R., Linn F.V., et al. Nosocomial Clostridium difficile colonisation and disease. Lancet 336 8707 (1990) 97-100
34. Clabots C.R., Johnson S., Olson M.M., et al. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 166 3 (1992) 561-567
35. Riley T.V., Cooper M., Bell B., et al. Community-acquired Clostridium difficile-associated diarrhea. Clin Infect Dis 20 Suppl 2 (1995) S263-S265
36. Hirschhorn L.R., Trnka Y., Onderdonk A., et al. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 169 1 (1994) 127-133
37. Johnson S., and Gerding D.N. Clostridium difficile-associated diarrhea. Clin Infect Dis 26 5 (1998) 1027-1034 [quiz: 1035-26]
38. Kyne L., Sougioultzis S., McFarland L.V., et al. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 23 11 (2002) 653-659
39. Mulligan M.E., Miller S.D., McFarland L.V., et al. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis 16 Suppl 4 (1993) S239-S244
40. Kyne L., Warny M., Qamar A., et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342 6 (2000) 390-397
41. Shim J.K., Johnson S., Samore M.H., et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351 9103 (1998) 633-636
42. Warny M., Vaerman J.P., Avesani V., et al. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 62 2 (1994) 384-389
43. Wanahita A., Goldsmith E.A., Marino B.J., et al. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 115 7 (2003) 543-546
44. Kelly C.P., and LaMont J.T. Clostridium difficile infection. Annu Rev Med 49 (1998) 375-390
45. Bartlett J.G. Antibiotic-associated diarrhea. Clin Infect Dis 15 4 (1992) 573-581
46. Jacobs A., Barnard K., Fishel R., et al. Extracolonic manifestations of Clostridium difficile infections. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 80 2 (2001) 88-101
47. Veillard E., Guggenbuhl P., Bello S., et al. Reactive oligoarthritis in a patient with Clostridium difficile pseudomembranous colitis. Review of the literature. Rev Rhum Engl 65 12 (1998) 795-798
48. Thielman N.M.W.K. Mandell, Douglas and Bennett's principles and practices of infectious disease, vol 1. 6th edition (2005), Elsevier, Philadelphia (PA)
49. Palmore T.N., Sohn S., Malak S.F., et al. Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol 26 8 (2005) 680-684
50. Muto C.A., Pokrywka M., Shutt K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 26 3 (2005) 273-280
51. Schwaber M.J., Simhon A., Block C., et al. Factors associated with nosocomial diarrhea and Clostridium difficile-associated disease on the adult wards of an urban tertiary care hospital. Eur J Clin Microbiol Infect Dis 19 1 (2000) 9-15
52. McFarland L.V., Surawicz C.M., and Stamm W.E. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 162 3 (1990) 678-684
53. Nelson D.E., Auerbach S.B., Baltch A.L., et al. Epidemic Clostridium difficile-associated diarrhea: role of second- and third-generation cephalosporins. Infect Control Hosp Epidemiol 15 2 (1994) 88-94
54. Yip C., Loeb M., Salama S., et al. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 22 9 (2001) 572-575
55. McCusker M.E., Harris A.D., Perencevich E., et al. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 9 6 (2003) 730-733
56. Gaynes R., Rimland D., Killum E., et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 38 5 (2004) 640-645
57. Pepin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41 9 (2005) 1254-1260
58. Cunningham R., Dale B., Undy B., et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 54 3 (2003) 243-245
59. Dial S., Alrasadi K., Manoukian C., et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 171 1 (2004) 33-38
60. Dial S., Delaney J.A., Barkun A.N., et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294 23 (2005) 2989-2995
61. Al-Tureihi F.I., Hassoun A., Wolf-Klein G., et al. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc 6 2 (2005) 105-108
62. Thibault A., Miller M.A., and Gaese C. Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. Infect Control Hosp Epidemiol 12 6 (1991) 345-348
63. Brown E., Talbot G.H., Axelrod P., et al. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect Control Hosp Epidemiol 11 6 (1990) 283-290
64. Modena S., Bearelly D., Swartz K., et al. Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study. Infect Control Hosp Epidemiol 26 8 (2005) 685-690
65. Bliss D.Z., Johnson S., Savik K., et al. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 129 12 (1998) 1012-1019
66. Lyerly D.M., Neville L.M., Evans D.T., et al. Multicenter evaluation of the Clostridium difficile TOX A/B TEST. J Clin Microbiol 36 1 (1998) 184-190
67. Aldeen W.E., Bingham M., Aiderzada A., et al. Comparison of the TOX A/B test to a cell culture cytotoxicity assay for the detection of Clostridium difficile in stools. Diagn Microbiol Infect Dis 36 4 (2000) 211-213
68. McDonald L.C. Clostridium difficile: responding to a new threat from an old enemy. Infect Control Hosp Epidemiol 26 8 (2005) 672-675
69. Barbut F., Kajzer C., Planas N., et al. Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol 31 4 (1993) 963-967
70. Snell H., Ramos M., Longo S., et al. Performance of the TechLab C. DIFF CHEK-60 enzyme immunoassay (EIA) in combination with the C. difficile Tox A/B II EIA kit, the Triage C. difficile panel immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol 42 10 (2004) 4863-4865
71. O'Connor D., Hynes P., Cormican M., et al. Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol 39 8 (2001) 2846-2849
72. Doern G.V., Coughlin R.T., and Wu L. Laboratory diagnosis of Clostridium difficile-associated gastrointestinal disease: comparison of a monoclonal antibody enzyme immunoassay for toxins A and B with a monoclonal antibody enzyme immunoassay for toxin A only and two cytotoxicity assays. J Clin Microbiol 30 8 (1992) 2042-2046
73. Lozniewski A., Rabaud C., Dotto E., et al. Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of Premier Cytoclone A + B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains. J Clin Microbiol 39 5 (2001) 1996-1998
74. Alfa M.J., Swan B., VanDekerkhove B., et al. The diagnosis of Clostridium difficile-associated diarrhea: comparison of Triage C. difficile panel, EIA for Tox A/B and cytotoxin assays. Diagn Microbiol Infect Dis 43 4 (2002) 257-263
75. Arrow S.A., Croese L., Bowman R.A., et al. Evaluation of three commercial enzyme immunoassay kits for detecting faecal Clostridium difficile toxins. J Clin Pathol 47 10 (1994) 954-956
76. Bowman R.A., Arrow S., Croese L., et al. Evaluation of an enzyme immunoassay kit for the detection of Clostridium difficile enterotoxin. Pathology 26 4 (1994) 480-481
77. van den Berg R.J., Bruijnesteijn van Coppenraet L.S., Gerritsen H.J., et al. Prospective multicenter evaluation of a new immunoassay and real-time PCR for rapid diagnosis of Clostridium difficile-associated diarrhea in hospitalized patients. J Clin Microbiol 43 10 (2005) 5338-5340
78. Guilbault C., Labbe A.C., Poirier L., et al. Development and evaluation of a PCR method for detection of the Clostridium difficile toxin B gene in stool specimens. J Clin Microbiol 40 6 (2002) 2288-2290
79. Gerding D.N., Johnson S., Peterson L.R., et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 16 8 (1995) 459-477
80. Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 16 2 (1995) 105-113
81. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health Syst Pharm 55 13 (1998) 1407-1411
82. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 92 5 (1997) 739-750
83. Layton BAML, Gerding DN, Liedtke LA, et al. Changing patterns of Clostridium difficile disease: a report from infectious disease physicians. Paper presented at the 42nd Annual Meeting of the Infectious Disease Society of America. Boston, September 30-October 3, 2004.
84. Bricker E., Garg R., Nelson R., et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 1 (2005) CD004610
85. Teasley D.G., Gerding D.N., Olson M.M., et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 2 8358 (1983) 1043-1046
86. Bartlett J.G. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 6 Suppl 1 (1984) S235-S241
87. Nair S., Yadav D., Corpuz M., et al. Clostridium difficile colitis: factors influencing treatment failure and relapse-a prospective evaluation. Am J Gastroenterol 93 10 (1998) 1873-1876
88. Wallace J.F., Smith R.H., and Petersdorf R.G. Oral administration of vancomycin in the treatment of staphylococcal enterocolitis. N Engl J Med 272 (1965) 1014-1015
89. Khan M.Y., and Hall W.H. Staphylococcal enterocolitis-treatment with oral vancomycin. Ann Intern Med 65 1 (1966) 1-8
90. Tedesco F., Markham R., Gurwith M., et al. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 2 8083 (1978) 226-228
91. Silva Jr. J., Batts D.H., Fekety R., et al. Treatment of Clostridium difficile colitis and diarrhea with vancomycin. Am J Med 71 5 (1981) 815-822
92. Fekety R., Silva J., Buggy B., et al. Treatment of antibiotic-associated colitis with vancomycin. J Antimicrob Chemother 14 Suppl D (1984) 97-102
93. Fekety R., Silva J., Kauffman C., et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 86 1 (1989) 15-19
94. Young G.P., Ward P.B., Bayley N., et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 89 5 (1985) 1038-1045
95. Dudley M.N., McLaughlin J.C., Carrington G., et al. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch Intern Med 146 6 (1986) 1101-1104
96. de Lalla F., Nicolin R., Rinaldi E., et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 36 10 (1992) 2192-2196
97. Dzink J., and Bartlett J.G. In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis. Antimicrob Agents Chemother 17 4 (1980) 695-698
98. Biavasco F., Manso E., and Varaldo P.E. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 35 1 (1991) 195-197
99. Wong S.S., Woo P.C., Luk W.K., et al. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 34 1 (1999) 1-6
100. Cheng S.H., Chu F.Y., Lo S.H., et al. Antimicrobial susceptibility of Clostridium difficile by E test. J Microbiol Immunol Infect 32 2 (1999) 116-120
101. Barbut F., Decre D., Burghoffer B., et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 43 11 (1999) 2607-2611
102. Marchese A., Salerno A., Pesce A., et al. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 46 4 (2000) 253-266
103. Jamal W.Y., Mokaddas E.M., Verghese T.L., et al. In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait. Int J Antimicrob Agents 20 4 (2002) 270-274
104. Pelaez T., Alcala L., Alonso R., et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 46 6 (2002) 1647-1650
105. Cherry R.D., Portnoy D., Jabbari M., et al. Metronidazole: an alternate therapy for antibiotic-associated colitis. Gastroenterology 82 5 Pt 1 (1982) 849-851
106. Preventing the Spread of Vancomycin Resistance-Report from the Hospital Infection Control Practices Advisory Committee. Federal Register 1994;59(94):25758-63.
107. Gerding D.N. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection?. Clin Infect Dis 25 Suppl 2 (1997) S206-S210
108. Wenisch C., Parschalk B., Hasenhundl M., et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 22 5 (1996) 813-818
109. Olsson-Liljequist B., and Nord C.E. In vitro susceptibility of anaerobic bacteria to nitroimidazoles. Scand J Infect Dis Suppl 26 (1981) 42-45
110. Brazier J.S., Fawley W., Freeman J., et al. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 48 5 (2001) 741-742
111. Sanchez J.L.G.D., Olson M.M., and Johnson S. Metronidazole susceptibility in Clostridium difficile isolates recovered from cases of C. difficile-associated disease treatment failures and successes. Anaerobe 5 (1999) 205-208
112. Mattila J., Mannisto P.T., Mantyla R., et al. Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route. Antimicrob Agents Chemother 23 5 (1983) 721-725
113. Loft S., Dossing M., Poulsen H.E., et al. Influence of dose and route of administration on disposition of metronidazole and its major metabolites. Eur J Clin Pharmacol 30 4 (1986) 467-473
114. Bolton R.P., and Culshaw M.A. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27 10 (1986) 1169-1172
115. Friedenberg F., Fernandez A., Kaul V., et al. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 44 8 (2001) 1176-1180
116. Chang T.W., Gorbach S.L., Bartlett J.G., et al. Bacitracin treatment of antibiotic-associated colitis and diarrhea caused by Clostridium difficile toxin. Gastroenterology 78 6 (1980) 1584-1586
117. de Lalla F., Privitera G., Rinaldi E., et al. Treatment of Clostridium difficile-associated disease with teicoplanin. Antimicrob Agents Chemother 33 7 (1989) 1125-1127
118. Wullt M., and Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 54 1 (2004) 211-216
119. Rossignol J.F., and Maisonneuve H. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections. Am J Trop Med Hyg 33 3 (1984) 511-512
120. Rossignol J.F., Hidalgo H., Feregrino M., et al. A double-'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 92 6 (1998) 663-666
121. Rossignol J.F., Ayoub A., and Ayers M.S. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 184 3 (2001) 381-384
122. Rossignol J.F., Ayoub A., and Ayers M.S. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 184 1 (2001) 103-106
123. McVay C.S., and Rolfe R.D. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 44 9 (2000) 2254-2258
124. Dubreuil L., Houcke I., Mouton Y., et al. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 40 10 (1996) 2266-2270
125. Musher DM, Logan N, Hanill RJ, et al. Nitazoxanide in the treatment of Clostridium difficile colitis. Clinical Infectious Diseases, in press.
126. Louie TJ. Treating Clostridium difficile in the future: what's coming? Paper presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: 2005.
127. Trudel J.L., Deschenes M., Mayrand S., et al. Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum 38 10 (1995) 1033-1038
128. Elinav E., Planer D., and Gatt M.E. Prolonged ileus as a sole manifestation of pseudomembranous enterocolitis. Int J Colorectal Dis 19 3 (2004) 273-276
129. Salcedo J., Keates S., Pothoulakis C., et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41 3 (1997) 366-370
130. Wilcox M.H. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 53 5 (2004) 882-884
131. Babcock GJMR, Coccia JA, Esshaki DJ, et al. Human monoclonal antibody against toxin A protects hamsters from Clostridium difficile disease. Paper presented at the 42nd Annual Meeting of the Infectious Disease Society of America. Boston, September 30-October 3, 2004.
132. Bartlett J.G., Chang T.W., and Onderdonk A.B. Comparison of five regimens for treatment of experimental clindamycin-associated colitis. J Infect Dis 138 1 (1978) 81-86
133. Mogg G.A., Arabi Y., Youngs D., et al. Therapeutic trials of antibiotic associated colitis. Scand J Infect Dis Suppl Suppl 22 (1980) 41-45
134. Mogg G.A., George R.H., Youngs D., et al. Randomized controlled trial of colestipol in antibiotic-associated colitis. Br J Surg 69 3 (1982) 137-139
135. Taylor N.S., and Bartlett J.G. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 141 1 (1980) 92-97
136. Braunlin W., Xu Q., Hook P., et al. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Biophys J 87 1 (2004) 534-539
137. Cavagnaro C., Berezin S., and Medow M.S. Corticosteroid treatment of severe, non-responsive Clostridium difficile induced colitis. Arch Dis Child 88 4 (2003) 342-344
138. Bartlett J.G., Tedesco F.J., Shull S., et al. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology 78 3 (1980) 431-434
139. McFarland L.V., Surawicz C.M., Greenberg R.N., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271 24 (1994) 1913-1918
140. Fekety R., McFarland L.V., Surawicz C.M., et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 24 3 (1997) 324-333
141. Fernandez A., Anand G., and Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol 38 5 (2004) 414-418
142. Johnson S., Adelmann A., Clabots C.R., et al. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis 159 2 (1989) 340-343
143. O'Neill G.L., Beaman M.H., and Riley T.V. Relapse versus reinfection with Clostridium difficile. Epidemiol Infect 107 3 (1991) 627-635
144. Barbut F., Richard A., Hamadi K., et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 38 6 (2000) 2386-2388
145. Tang-Feldman Y., Mayo S., Silva Jr. J., et al. Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent clostridium difficile-associated diarrhea. J Clin Microbiol 41 7 (2003) 3413-3414
146. Noren T., Akerlund T., Back E., et al. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J Clin Microbiol 42 8 (2004) 3635-3643
147. McFarland L.V., Elmer G.W., and Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97 7 (2002) 1769-1775
148. Buggy B.P., Fekety R., and Silva Jr. J. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 9 2 (1987) 155-159
149. Persky S.E., and Brandt L.J. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol 95 11 (2000) 3283-3285
150. Aas J., Gessert C.E., and Bakken J.S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36 5 (2003) 580-585
151. Seal D., Borriello S.P., Barclay F., et al. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol 6 1 (1987) 51-53
152. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 95 1 Suppl (2000) S11-S13
153. Wullt M., Hagslatt M.L., and Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 35 6-7 (2003) 365-367
154. Plummer S., Weaver M.A., Harris J.C., et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 7 1 (2004) 59-62
155. D'Souza A.L., Rajkumar C., Cooke J., et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 324 7350 (2002) 1361
156. Beales I.L. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut 51 3 (2002) 456
157. Leung D.Y., Kelly C.P., Boguniewicz M., et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 118 4 Pt 1 (1991) 633-637
158. Delmee M., Vandercam B., Avesani V., et al. Epidemiology and prevention of Clostridium difficile infections in a leukemia unit. Eur J Clin Microbiol 6 6 (1987) 623-627
159. Kerr R.B., McLaughlin D.I., and Sonnenberg L.W. Control of Clostridium difficile colitis outbreak by treating asymptomatic carriers with metronidazole. Am J Infect Control 18 5 (1990) 332-335
160. Johnson S., Homann S.R., Bettin K.M., et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 117 4 (1992) 297-302
161. Zafar A.B., Gaydos L.A., Furlong W.B., et al. Effectiveness of infection control program in controlling nosocomial Clostridium difficile. Am J Infect Control 26 6 (1998) 588-593
162. Kaatz G.W., Gitlin S.D., Schaberg D.R., et al. Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol 127 6 (1988) 1289-1294
163. Mayfield J.L., Leet T., Miller J., et al. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 31 4 (2000) 995-1000
164. Wilcox M.H., Fawley W.N., Wigglesworth N., et al. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect 54 2 (2003) 109-114
165. Brooks S.E., Veal R.O., Kramer M., et al. Reduction in the incidence of Clostridium difficile-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. Infect Control Hosp Epidemiol 13 2 (1992) 98-103
166. McNulty C., Logan M., Donald I.P., et al. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 40 5 (1997) 707-711
167. Carling P., Fung T., Killion A., et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 24 9 (2003) 699-706
168. Pear S.M., Williamson T.H., Bettin K.M., et al. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 120 4 (1994) 272-277
169. Climo M.W., Israel D.S., Wong E.S., et al. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 128 12 Pt 1 (1998) 989-995
170. O'Connor K.A., Kingston M., O'Donovan M., et al. Antibiotic prescribing policy and Clostridium difficile diarrhoea. QJM 97 7 (2004) 423-429
171. Wilcox M.H., Freeman J., Fawley W., et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother 54 1 (2004) 168-172
172. Khan R., and Cheesbrough J. Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital. J Hosp Infect 54 2 (2003) 104-108
173. Torres J.F., Lyerly D.M., Hill J.E., et al. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun 63 12 (1995) 4619-4627
174. Ryan E.T., Butterton J.R., Smith R.N., et al. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect Immun 65 7 (1997) 2941-2949
175. Ward S.J., Douce G., Figueiredo D., et al. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect Immun 67 5 (1999) 2145-2152
176. Pavliakova D., Moncrief J.S., Lyerly D.M., et al. Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice. Infect Immun 68 4 (2000) 2161-2166
177. Aboudola S., Kotloff K.L., Kyne L., et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 71 3 (2003) 1608-1610
178. Sougioultzis S., Kyne L., Drudy D., et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128 3 (2005) 764-770
179. Eggertson L. Quebec strain of C. difficile in 7 provinces. CMAJ 174 5 (2006) 607-608
180. Pepin J., Valiquette L., and Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173 9 (2005) 1037-1042